Status:
COMPLETED
Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux
Lead Sponsor:
University of California, Davis
Conditions:
Laryngopharyngeal Reflux
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifica...
Detailed Description
Laryngopharyngeal reflux (LPR) is a disorder caused by acid-induced damage to the larynx and pharynx (voice box and throat). The standard care for persons with this disorder is treatment with highly p...
Eligibility Criteria
Inclusion
- patients with a clinical diagnosis of laryngopharyngeal reflux diagnosed by any combination of patient symptoms, physical/endoscopic findings, and 24 hr dual-probe ambulatory pH-testing.
- 18 years of age or older
Exclusion
- patients with life-threatening complications of laryngeal, pharyngeal or esophageal cancer, subglottic or tracheal stenosis, laryngeal papilloma, airway compromise
- elite vocal performs with LPR-related dysphonia
- under 18 years of age
- pregnant and/or lactating women
- persons with known hypersensitivity to any component of the formulation
- patients taking theophylline, ketoconazole, ampicillin or digoxin
- persons with hepatic and renal insufficiency
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT00864396
Start Date
July 1 2005
End Date
May 1 2008
Last Update
March 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Davis Medical Center
Sacramento, California, United States, 95817